NCT07107373View on ClinicalTrials.gov

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Active, not recruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

July 26, 2024

Study Completion Date

December 31, 2025

Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
DRUG

Mavacamten

According to the product label

Trial Locations (1)

94118

University of California, San Francisco (UCSF), San Francisco

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY